Navigation Links
Commonly Prescribed Drugs May Influence the Onset and Progression of Alzheimer’s Disease
Date:6/12/2013

New York, NY (PRWEB) June 12, 2013

Multiple drug classes commonly prescribed for common medical conditions are capable of influencing the onset and progression of Alzheimer’s disease, according to researchers at The Mount Sinai Medical Center. The findings are published online in the journal PLoS One.

Led by Giulio Maria Pasinetti, MD, PhD, the Saunders Family Chair and Professor in Neurology at Mount Sinai, a research team used a computer algorithm to screen 1,600 commercially available medications to assess their impact on the brain accumulation of beta-amyloid, a protein abnormally accumulated in the brain of Alzheimer’s disease and implicated in neurodegeneration. They found that currently available medications prescribed for conditions such as hypertension, depression, and insomnia were found to either block or enhance the accumulation of beta-amyloid, the component of amyloid plaques.

“This line of investigation will soon lead to the identification of common medications that might potentially trigger conditions associated with the prevention, or conversely the onset, of Alzheimer’s disease,” said Dr. Pasinetti. “They may be a novel reference for physicians to consider when prescribing the most appropriate drug, particularly in subjects at high risk for Alzheimer’s disease.”

To validate the screening protocol, Dr. Pasinetti and his colleagues administered these drugs in mice that were genetically engineered to develop the hallmark amyloid plaques associated with Alzheimer’s disease. After six months of treatment with blood pressure medicines, amyloid plaques and neurodegeneration were significantly reduced in the mice. One such medicine was Carvedilol, now under clinical investigation in Alzheimer ’s disease with the intent to slow down memory deterioration.

“In recent years, amyloid plaques have become one of the main focal points in the search to understand and to treat Alzheimer’s disease," said Dr. Pasinetti. “Thus, identifying novel drug treatments that prevent harmful beta-amyloid generation will help in the development of treatments for Alzheimer’s disease. For example, one very exciting finding of our study is that Carvedilol, already approved for treatment of hypertension, may immediately become a promising drug for the treatment of Alzheimer’s as well.”

The authors discuss the limitations of the research, noting that studies must be immediately verified in human-safety studies that examine the effects of the drugs independent of the original indication. Dr. Pasinetti hopes these findings will lead to multiple clinical trials in the future to identify preventive drugs, which will need to be prescribed at tolerable dosages.

“If we can repurpose drugs currently used for different indications, such as lowering blood pressure, this could have dramatic implications for this population,” said Dr. Pasinetti.

The study was supported by a grant from the National Institutes of Health (Grant UO1-AG029310).

About The Mount Sinai Medical Center

The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Icahn School of Medicine at Mount Sinai. Established in 1968, the Icahn School of Medicine at Mount Sinai is one of the leading medical schools in the United States. The Icahn School of Medicine is noted for innovation in education, biomedical research, clinical care delivery, and local and global community service. It has more than 3,400 faculty members in 32 departments and 14 research institutes, and ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by U.S. News & World Report.

The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation’s oldest, largest and most-respected voluntary hospitals. In 2012, U.S. News & World Report ranked The Mount Sinai Hospital 14th on its elite Honor Roll of the nation’s top hospitals based on reputation, safety, and other patient-care factors. Mount Sinai is one of just 12 integrated academic medical centers whose medical school ranks among the top 20 in NIH funding and by U.S. News & World Report and whose hospital is on the U.S. News & World Report Honor Roll. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 560,000 outpatient visits took place.

For more information, visit http://www.mountsinai.org.
Find Mount Sinai on:
Facebook: http://www.facebook.com/mountsinainyc
Twitter @mountsinainyc
YouTube: http://www.youtube.com/mountsinainy

Read the full story at http://www.prweb.com/releases/2013/6/prweb10827566.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Commonly used painkillers may protect against skin cancer
2. Condition Commonly Seen in Aging May Alter Brain Function
3. New UAlberta research shows commonly prescribed medications could have adverse effects
4. UV Flash Infection Control Unit Steps onto the Healthcare Market, with a Quick and Effective Way to Disinfect Virtually any Item Commonly Found in Medical Facilities
5. Commonly used cholesterol calculation underestimates heart disease danger for many
6. Commonly used drug can limit radiation damage to lungs and heart for cancer patients
7. Middle-aged women commonly become ill with stress
8. Commonly-prescribed drugs may influence the onset and progression of Alzheimers disease
9. Not taking gastroprotective drugs prescribed with anti-inflammatory medicines
10. New federal disclosure law may have little impact on drugs prescribed
11. More U.S. Kids Prescribed Off-Label Antipsychotics: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... entered a settlement agreement to resolve the pending litigation between itself and 1800 ... the District of Utah). , “I am thrilled to announce that we have ...
(Date:3/27/2017)... ... March 27, 2017 , ... From 1999 ... alone responsible for over 33,000 of the 52,404 drug-related deaths in 2015.(2) To ... 1512, which proposes a tax on prescription opioids to fund drug rehabilitation and ...
(Date:3/27/2017)... ... March 27, 2017 , ... Harris Communications, Inc., a leading provider of ... products to the Deaf Seniors of America Conference, April 4-7 at the Hotel Westin ... knowledgeable ASL friendly staff from Harris Communications and to try out the newest assistive ...
(Date:3/25/2017)... Square, PA (PRWEB) , ... March 25, 2017 , ... ... priority as a public relations partner. , All through the year, Garden Media ... and press releases, working with key influencers and pitching client’s key messages ...
(Date:3/24/2017)... ... March 24, 2017 , ... Clean Earth, ... material, and hazardous and non-hazardous materials announced today the acquisition of privately owned ... will add four additional processing facilities and a vast array of additional technologies, ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Germany , March 27, 2017 ... over 7,000 attendees and more than 600 exhibitors ... and discover opportunities and solutions that will advance ... 6 April 2017 at the Messe Stuttgart, ... the preeminent medical technology platform showcasing the key ...
(Date:3/27/2017)... CHICAGO , March 27, 2017  A ... Educators (AADE) found that Medicare,s Competitive Bidding Program (CBP) ... diabetes testing supplies. The lack of choice forces beneficiaries ... can have dire health consequences. AADE,s ... reports by AADE and others pointing out the inherent ...
(Date:3/27/2017)... YORK , March 27, 2017 FinancialBuzz.com News ... According to a new ... North America , grew 34 percent to $6.7 billion and ... rate of (CAGR) over the next five years, from $6.7 billion in ... of Americans that will be able to purchase cannabis without a doctor,s ...
Breaking Medicine Technology: